Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases-Reference-Cited by-同舟云学术

Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases

Published:2015-09-13 Issue:10 Volume:42 Page:1158-1169
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Papamichael K.¹²,Van Stappen T.¹,Jairath V.³,Gecse K.⁴,Khanna R.⁵,D'Haens G.⁵⁶,Vermeire S.²,Gils A.¹,Feagan B. G.⁵,Levesque B. G.⁵⁷,Vande Casteele N.¹⁷

Affiliation:

1. KU Leuven Department of Pharmaceutical and Pharmacological Sciences; Leuven Belgium

2. KU Leuven Department of Clinical and Experimental Medicine; Leuven Belgium

3. Translational Gastroenterology Unit; Nuffield Department of Medicine; John Radcliffe Hospital; University of Oxford; Oxford UK

4. 1st Department of Medicine; Semmelweis University; Budapest Hungary

5. Robarts Clinical Trials Inc.; London ON Canada

6. Department of Gastroenterology and Hepatology; Academic Medical Centre; University of Amsterdam; Amsterdam The Netherlands

7. Division of Gastroenterology; University of California San Diego; La Jolla CA USA

Funder

Hellenic Society of Gastroenterology

European Crohn's and Colitis Organisation (ECCO)

Agentschap voor Innovatie door Wetenschap en Technologie

UK National Institute for Health Research

Fonds Wetenschappelijk Onderzoek

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.13402/fullpdf

Reference69 articles.

1. Targeting TNF-alpha for the treatment of inflammatory bowel disease;Billiet;Expert Opin Biol Ther,2014

2. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases;Willrich;Transl Res,2015

3. The state of the art in the development of biosimilars;McCamish;Clin Pharmacol Ther,2012

4. Acceptable changes in quality attributes of glycosylated biopharmaceuticals;Schiestl;Nat Biotechnol,2011

5. EMA/CHMP Guideline on similar biological medicinal products http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of biosimilar infliximab in bio-naïve patients with Crohn’s disease;Arab Journal of Gastroenterology;2024-08

2. Therapeutic Applications of Extracellular Vesicles in Inflammatory Bowel Disease;International Journal of Molecular Sciences;2024-01-06

3. HLA-DQA1*05 and upstream variants of PPARGC1B are associated with infliximab persistence in Japanese Crohn’s disease patients;The Pharmacogenomics Journal;2023-07-17

4. HLA-DQA1*05 and upstream variants of PPARGC1B are associated with infliximab persistence in Japanese Crohn’s disease patients;2023-04-06

5. Biologics for Inflammatory Bowel Disease in Clinical Practice: A Calabria (Southern Italy) Prospective Pharmacovigilance Study;Pharmaceutics;2022-11-13